Market Overview

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Boston Scientific Corporation

Related BSX
Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device
Benzinga's Top Initiations

In a report published Wednesday, Citigroup reiterated its Buy rating on Boston Scientific Corporation (NYSE: BSX), and slightly raised its price target from $7.30 to $8.20.

Citigroup noted, “BSX's shares have moved up significantly faster than we expected since last Thanksgiving, but we still see room for the stock on a fundamental basis as trends are improving and the peer group valuation has moved up. Plus, we still believe the call option on Durata being removed from the market is largely underappreciated.”

Boston Scientific Corporation closed on Tuesday at $7.10.

Latest Ratings for BSX

Nov 2015CitigroupInitiates Coverage onBuy
Oct 2015BarclaysMaintainsOverweight
Oct 2015Raymond JamesDowngradesOutperformStrong Buy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings


Related Articles (BSX)

Get Benzinga's Newsletters